We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- 3 or more groups
- Groups are ‘completely ordered’
- Yuan and Chappell (2004) (1)
- Yuan and Chappell (2004) (2)
- Yuan and Chappell (2004) (3)
- ‘Isotonizing’ the estimates
- Dose allocation (1)
- Partially ordered groups
- Innocenti et al. (2014)
- Methods for partially or completely ordered groups
- Conaway (2017a, Stats in Med): Step 1
- Conaway (2017a, Stats in Med): Step 2
- Estimation
- Avoiding reversals
- Examples of permissible allocations (1)
- Examples of permissible allocations (2)
- Dose allocation (2)
- Another combination of order restrictions and CRM
- Conaway (2017b, Clin Trials)
- Examples
- Relationship to Yuan and Chappell method
- Summary
- References
Topics Covered
- More than two ordered groups
- Completely ordered groups
- Partially ordered groups
- Methods for ordered groups
- Dose allocations
Talk Citation
Conaway, M. (2018, June 28). Patient heterogeneity in dose-finding trials - part 2: more than 2 groups [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/JPCS9843.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Mark Conaway has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Patient heterogeneity in dose-finding trials - part 2: more than 2 groups
Published on June 28, 2018
20 min
Other Talks in the Series: Adaptive Clinical Trial Design
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Mark Conaway.
I'm a professor in the Division of Translational Research and Applied Statistics
in the Department of Public Health Sciences at the University of Virginia.
This talk is on Patient Heterogeneity and Dose-Finding trials.
Part two focuses on trials conducted in more than two groups.
There's also a part one that focuses on trials done in exactly two groups.
0:23
The outline for this talk is that I'll first provide
motivating examples for trials done in three or more groups,
and then I'll discuss some of
the existing statistical methods for the design of trials in three or more groups.
First, was published by Yuan and Chappell in 2004,
and then I'll talk about a couple of papers recently
published that discuss completely or partially ordered groups,
and I'll define what I mean by
completely or partially ordered groups in the context of dose-finding.
0:51
A study done in four groups presented by Ramanathan et al in 2008.
Prior to assigning doses,
patients were grouped into categories based
on the degree of liver dysfunction at baseline.
Patients were grouped into either none,
mild, moderate, severe levels of liver dysfunction.
A similar group was used in a dose-finding study reported by LoRusso et al in 2012.
1:15
In this case, the groups are what we call 'completely
ordered' in the sense that if you fix a dose level j,
you expect that the probability that a DLT at dose level dj among patients that have
no baseline liver dysfunction would be
less probability of a DLT at dose dj for patients with mild,
or moderate, or severe liver dysfunction.
Another way of thinking about completely ordered groups is you can say,
"Well, if you fix a dose,
you know completely the ordering of any two DLT probabilities from the different groups."
Hide